Stockreport

INSM Stock Plummets on Sinus Study Failure, Adds New Pipeline Asset [Yahoo! Finance]

Insmed, Inc.  (INSM) 
Last insmed, inc. earnings: 4/30 07:30 am Check Earnings Report
US:NASDAQ Investor Relations: investor.insmed.com
PDF This phase IIb study, called BiRCh, failed to achieve either its primary or secondary efficacy endpoints. Although the drug was well-tolerated in patients, the results [Read more]